%0 Journal Article
%T Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
%A Wada M
%A Zhang H
%A Fang L
%A Feng J
%A Tse CO
%A Zhang W
%A Chen Q
%A Sha S
%A Cao Y
%A Chen KH
%A Pinz KG
%A Chen X
%A Fan XX
%A Jiang X
%A Ma Y
%J Stem Cell Rev Rep
%V 16
%N 2
%D 04 2020
%M 32008159
%F 6.692
%R 10.1007/s12015-019-09937-9
%X T-cell malignancies often result in poor prognosis and outcome for patients. Immunotherapy has recently emerged as a revolutionary treatment against cancer, and the success seen in CD19 CAR clinical trials may extend to T cell diseases. However, a shared antigen pool coupled with the impact of T-cell depletion incurred by targeting T cell disease remain concepts to be clinically explored with caution. Here we report on the ability of T cells transduced with a CD5CAR to specifically and potently lyse malignant T-cell lines and primary tumors in vitro in addition to significantly improving in vivo control and survival of xenograft models of T-ALL. To extensively explore and investigate the biological properties of a CD5 CAR, we evaluated multiple CD5 CAR constructs and constructed 3 murine models to characterize the properties of CD5 down-regulation, the efficacy and specificity produced by different CD5 CAR construct designs, and the impact of incorporating a CD52 safety switch using CAMPATH to modulate the persistency and function of CAR cells. These data support the potential use of CD5CAR T cells in the treatment of T cell malignancies or refractory disease in clinical settings.